Qualidade de vida em tratamento de lúpus eritematoso sistêmico com antimaláricos

Furlan, Fernanda Luzia Schumacher; Lemes, Macleise Andres; Pires, Carolina Teixeira Furquim; Azevedo, Gabriela; Bernardi, Gisele Ferreira; Simões, Yaçaña Siqueira; Dias, Márcia Regina Messagi Gomes; Skare, Thelma Larocca.
Rev. Soc. Bras. Clín. Méd ; 16(1): 2-6, 20180000. tab, ilus
Artigo em Português | LILACS | ID: biblio-884974

Documentos relacionados

  1. [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
  2. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
  3. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
  4. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
  5. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
  6. The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome.
  7. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
  8. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
  9. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
  10. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: Review and Appraisal of Current Evidence.